The Dermis as a Portal for Dendritic Cell-Targeted Immunotherapy of Cutaneous Melanoma

2011 ◽  
pp. 181-220 ◽  
Author(s):  
D. Oosterhoff ◽  
B. J. R. Sluijter ◽  
B. N. Hangalapura ◽  
T. D. de Gruijl
Keyword(s):  
Dendritic Cell ◽  
Cutaneous Melanoma ◽  
Targeted Immunotherapy

scholarly journals Relapse of tagraxofusp treated blastic plasmacytoid dendritic cell neoplasm with loss of CD123 expression

2021 ◽  
Author(s):  
Rohit Gulati ◽  
Asma Abu-Salah ◽  
Tareq Salous ◽  
Mehdi Nassiri
Keyword(s):  
Bone Marrow ◽  
Flow Cytometry ◽  
Dendritic Cell ◽  
Plasmacytoid Dendritic Cell ◽  
Primary Treatment ◽  
Resistance Mechanisms ◽  
Elderly Male ◽  
Bone Marrow Specimen ◽  
Cell Neoplasm ◽  
Targeted Immunotherapy

AbstractTagraxofusp, a CD123-based-targeted immunotherapy, was recently approved to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) with excellent response. Also, a subset of BPDCN shows resistance to tagraxofusp. These resistant cases continue to express CD123, which forms the basis of the continued utility of tagraxofusp in newer combination chemotherapies to overcome resistance in BPDCN. Herein, we report a case of an elderly male with BPDCN that achieved complete remission on initial primary treatment with tagraxofusp. However, BPDCN relapsed after 1.5 years while on treatment, with loss of CD123 expression. At relapse, the neoplasm was comprehensively immunophenotyped by flow cytometry (performed on both peripheral blood and bone marrow specimen) and by immunohistochemical evaluation of the bone marrow clot section. The neoplasm at relapse was diagnostic of BPDCN with a lack of CD123 expression. This case highlights a potential limitation of current and upcoming tagraxofusp-based multidrug therapies, at least in a subset of refractory BPDCN. We believe our report will serve as a sentinel to incite future investigations involving alternate resistance mechanisms in BDPCN.

scholarly journals Tagraxofusp Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm With Loss of CD123 Expression: Case and Review of Literature

2021 ◽  
Author(s):  
Rohit Gulati ◽  
Asma Abu-Salah ◽  
Tareq Salous ◽  
Mehdi Nassiri
Keyword(s):  
Dendritic Cell ◽  
Complete Remission ◽  
Plasmacytoid Dendritic Cell ◽  
Primary Treatment ◽  
Resistance Mechanisms ◽  
Review Of Literature ◽  
Elderly Male ◽  
Case Presentation ◽  
Cell Neoplasm ◽  
Targeted Immunotherapy

Abstract Background: Tagraxofusp, a CD123 based targeted immunotherapy, was recently approved to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) with excellent response. Also, a subset of BPDCN showed resistance to tagraxofusp. These resistant cases continue to express CD123, which forms the basis of the continued utility of tagraxofusp in newer combination chemotherapies to overcome resistance in BPDCN. Case presentation: Herein we report a case of an elderly male with BPDCN that initially achieved complete remission on primary treatment with tagraxofusp. However, BPDCN relapsed after 1.5 years while on treatment with loss of CD123 expression. Conclusions: This case highlights a potential limitation of current and upcoming tagraxofusp based therapies, at least in a subset of refractory BPDCN. We believe our report will serve as a sentinel to incite future investigations involving alternate resistance mechanisms in BDPCN.

Abstract 1746: Designing a dendritic cell-targeted immunotherapy for the treatment of pancreatic ductal adenocarcinoma

2021 ◽  
Author(s):  
Ron Kleiner ◽  
Daniella Vaskovich ◽  
Sabina Pozzi ◽  
Anat Eldar-Boock ◽  
Dikla Ben-Shushan ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Targeted Immunotherapy

Cutaneous melanoma in a patient with neurofibromatosis

1979 ◽  
Vol 115 (7) ◽  
pp. 864-865 ◽  
Author(s):  
M. J. Mastrangelo
Keyword(s):  
Cutaneous Melanoma
Sign in / Sign up

Export Citation Format

Share Document